Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Exicure Inc XCUR

Healthcare Biotechnology
Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Recent & Breaking News (NDAQ:XCUR)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

GlobeNewswire 10 days ago

Exicure, Inc. Reports Full Year 2025 Financial Results

GlobeNewswire March 25, 2026

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

GlobeNewswire February 5, 2026

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

GlobeNewswire January 21, 2026

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

GlobeNewswire December 8, 2025

Exicure, Inc. Reports Third Quarter 2025 Financial Results

GlobeNewswire November 7, 2025

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

GlobeNewswire November 3, 2025

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Business Wire October 22, 2025

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

GlobeNewswire October 6, 2025

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Business Wire August 8, 2025

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Business Wire August 4, 2025

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business Wire August 1, 2025

Exicure, Inc. Reports First Quarter 2025 Financial Results

Business Wire June 27, 2025

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Business Wire May 28, 2025

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Business Wire May 5, 2025

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Business Wire April 14, 2025

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Business Wire April 11, 2025

Exicure, Inc. Reports Full Year 2024 Financial Results

Business Wire March 18, 2025

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Business Wire March 13, 2025

Kuehn Law Encourages Investors of Exicure, Inc. to Contact Law Firm

Newsfile January 27, 2025

Podcasts